Sugi Predict

Sugi Predict / Compounds / SCHEMBL259689

SCHEMBL259689

SCHEMBL259689

O=C(O)c1cccc2cn[nH]c12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK4 O00444 1/20 0.72
▸ CHEK1 O14757 1/20 0.72
▸ AURKA O14965 1/20 0.72
▸ DAPK3 O43293 1/20 0.72
▸ MAP4K4 O95819 1/20 0.72
▸ CSF1R P07333 1/20 0.72
▸ RET P07949 1/20 0.72
▸ FGFR1 P11362 1/20 0.72
▸ PDGFRA P16234 1/20 0.72
▸ LTK P29376 1/20 0.72
▸ KDR P35968 1/20 0.72
▸ MAP2K2 P36507 1/20 0.72
▸ FLT3 P36888 1/20 0.72
▸ CSNK1A1 P48729 1/20 0.72
▸ PRKX P51817 1/20 0.72
▸ CDK5 Q00535 1/20 0.72
▸ MAP2K1 Q02750 1/20 0.72
▸ MST1R Q04912 1/20 0.72
▸ PTK2 Q05397 1/20 0.72
▸ BTK Q06187 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29520722 1.00 PLK4 (0.72) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL30809709 0.85 PLK4 (0.58) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL29696521 0.84 PLK4 (1.00) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL20616534 0.84 PLK4 (0.70) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL3386425 0.84 PLK4 (0.70) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL2264295 0.84 PLK4 (1.00) PLK4CHEK1AURKADAPK3MAP4K4
Oxalic Acid SCHEMBL28217953 0.83 PLK4 (0.90) PLK4CHEK1AURKADAPK3MAP4K4
Lithium Ion SCHEMBL30135624 0.82 PLK4 (0.68) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL24992498 0.82 PLK4 (0.62) PLK4CHEK1AURKADAPK3MAP4K4
SCHEMBL10593966 0.82 DAPK3 (0.54) PLK4CHEK1AURKADAPK3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 — — CN claimed
CN-117050300-A Polylysine-based polymer adjuvant material, and preparation method and application thereof 中国科学院长春应用化学研究所 2023-11-14 — — CN claimed
WO-2022064459-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS OF USING SAME 1ST Biotherapeutics, Inc. (KR) 2022-03-31 — — WO claimed
CN-113603886-A Polyethyleneimine derivative and preparation method and application thereof 中国科学院长春应用化学研究所 2021-11-05 — — CN claimed
EP-3288940-B9 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-07-21 — — EP claimed
EP-3288940-B1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-02-24 — — EP claimed
EP-2903978-A1 GDF-8 INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2015-08-12 — — EP claimed
WO-2014055955-A1 GDF-8 INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2014-04-10 — — WO claimed
CN-102083827-A Thiazolidine compounds as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD 2011-06-01 — — CN claimed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 — — US claimed
EP-2291076-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2011-03-09 — — EP claimed
WO-2009140111-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2009-11-19 — — WO claimed
CN-101541757-A Pyrazolines as Mineralocorticoid Receptor Antagonists PFIZER PROD INC (US) 2009-09-23 — — CN claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 — — EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
WO-2004093872-A1 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2004-11-04 — — WO disclosed
US-20040132790-A1 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof MEMORY PHARMACEUTICALS CORPORATION 2004-07-08 — — US disclosed
WO-2004029050-A1 INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2004-04-08 — — WO disclosed
CN-1059144-A New tricyclic compound or its salt, prepare their method and contain their antiseptic-germicide WAKUNAGA SEIYAKU KK (JP) 1992-03-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR PLK4 3139/4885CHEK1 4565/4885AURKA 2739/4885
US-20040132790-A1 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof CHRNA5, CHRNA7, CHRNA3 PLK4 3769/4885CHEK1 2004/4885AURKA 2136/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PLK4 3458/4885CHEK1 2323/4885AURKA 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.